USA – Include cancer patients in COVID-19 vaccine trials, say ASCO and Friends of Cancer Research

People with cancer should be included in COVID-19 vaccine clinical trials, according to a new joint position statement from the American Society of Clinical Oncology (ASCO) and the Friends of Cancer Research (FCR).
 
“We’ve learned that patients with cancer are especially vulnerable to severe illness, hospitalization, or death due to COVID-19,” said ASCO President Everett E. Vokes in a joint press release announcing the position statement. “It is critically important to study adequate numbers of patients who have cancer or a history of cancer so that we can better understand the degree to which patients with cancer, various kinds of immunocompromise, or both respond to vaccines.”
 
The joint statement builds on other work from both organizations that supports broadening eligibility criteria for cancer clinical trial participation. “We continue to emphasize that broadening eligibility criteria to clinical trials will help inform the optimal use of new medicines for more people, and the same principles apply to COVID-19 vaccines,” said Jeff Allen, president and CEO of FCR. (RELATED: AACR: Minority accrual in clinical trials is a team sport, Regulatory Focus 23 June 2020)…